Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / GLSI - Greenwich LifeSciences: Optimism On 'GP2' Breast Cancer Immunotherapy Candidate

GLSI - Greenwich LifeSciences: Optimism On 'GP2' Breast Cancer Immunotherapy Candidate

Greenwich LifeSciences Inc.
  • Shares of GLSI are up nearly 600% over the past month with market enthusiasm over phase 2b trial data for its 'GP2' breast cancer immunotherapy.
  • GP2 may be able to reduce breast cancer recurrence rate to 0% over 5-years, representing a significant clinical advantage to alternatives on the market.
  • Planned Phase 3 trial expected to start in 2021 and separate studies for additional cancer indications highlight upcoming catalysts to watch for in 2021.

For further details see:

Greenwich LifeSciences: Optimism On 'GP2' Breast Cancer Immunotherapy Candidate
Stock Information
Company Name: Greenwich LifeSciences Inc.
Stock Symbol: GLSI
Market: NASDAQ
Website: greenwichlifesciences.com
Menu
GLSI GLSI Quote GLSI Short GLSI News GLSI Articles GLSI Message Board
Get GLSI Alerts

News, Short Squeeze, Breakout and More Instantly...